RT Journal Article
SR Electronic
T1 ALBUMIN CREATININE RATIO IN TYPE 2 DIABETES MELLITUS IN BARBADOS: ALBUMIN CREATININE RATIO AS AN INDICATOR OF NON-HEALING FOOT WOUND FORMATION IN DIABETES
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.01.21264433
DO 10.1101/2021.10.01.21264433
A1 André R Greenidge
A1 Kim R Quimby
A1 Amy P Speede
A1 Ian R Hambleton
A1 Simon G Anderson
A1 R Clive Landis
YR 2021
UL http://medrxiv.org/content/early/2021/10/04/2021.10.01.21264433.abstract
AB Aims To investigate whether kidney injury, determined by albumin creatinine ratio, was associated with current non-healing foot wounds in type 2 diabetes.Materials and Methods Eighty-nine Barbadians with diabetes were recruited. Cases had a current foot wound and controls had no current foot wound and no history of a non-healing foot wound. Cases were matched to controls using sex, age and duration of diabetes. Participants were from wound dressing and diabetes clinics at the Queen Elizabeth Hospital and Polyclinics, and from private healthcare practitioners. The relationship between albumin creatinine ratio and foot ulceration, adjusting for selected potential risk factors, was analyzed using logistic regression and presented as odds ratios.Results Forty-four cases and 45 controls were matched, with no statistically significant difference in matching criteria. There were statistically important differences in measures of neuropathy, blood glucose, HbA1c and Albumin:creatinine ratio between cases and controls. Cases were 3 times more likely than controls to have microalbuminuria (95% CI 0.9 – 10.2; p=0.08). Cases were 7.4 times more likely than controls to have macroalbuminuria (95% CI 1.2 – 47.5; p=0.04).Conclusions The possible association of albumin:creatinine ratio with diabetic foot wounds raises the possibility of its use in earlier identification of persons on the pathway to developing diabetic foot.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for the WHY study was provided by the following institutions and companies: The Barbados Diabetes Foundation; Cave-Shepherd Ltd Barbados; Destiny Group of Companies, Canada; Bayer Pharmaceuticals Ltd, USA; Medicor International, UK. Core laboratory support was also received from Mr Peter Cohen and the late Mr Edmund Cohen, UK. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human investigations in this study were conducted according to the principles expressed in the Declaration of Helsinki. Ethical approval was granted from both the Ministry of Health and the Institutional Review Board of the Ministry of Health and the University of the West Indies.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDr. Andre Greenidge is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.